Evaluation of Pegfilgrastim for Stem Cell Mobilization in Children

Summary

Hypothesis: pegfilgrastim at 300 µg/kg in hematological steady state provides an efficient stem cell mobilization in children with malignancies Design: phase 2 study. Judgment criterion: percentage of children achieving at least 5x10e6 CD34 cells with a standard apheresis (less than 2 blood volume processed)

Timeline

Start

2006-01

Primary completion

2007-12

Completion

2008-01

Outcome

Outcome not reported

Stopped (Enrollment): “Recruiting or enrolling participants has halted and will not resume”

Drugs

Indications